This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

KTP-001

Teijin Pharma Limited

Drug Names(s): KTP-001

Description: KTP-001 shares a structure with the matrix metalloproteinase (MMP), an enzyme that promotes the spontaneous regression of hernia. KTP-001 is expected to achieve the regression of lumbar disc herniation with simple injections following conventional surgery.

Deal Structure: KTP-001 was developed jointly by Teijin Pharma and KAKETSUKEN (The Chemo-Sero-Therapeutic Research Institute).

Partners: Kaketsuken


KTP-001 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug